AI assistant
GlaxoSmithKline PLC — Director's Dealing 2017
Apr 19, 2017
5262_dirs_2017-04-19_a162fb1c-853d-47db-9f3a-f7df31129778.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7706C
GlaxoSmithKline PLC
19 April 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 82.730 (personal contribution) |
| £16.47 | 204.873 (personal contribution) |
| £16.47 | 223.059 (personal contribution) |
| £16.47 | 82.730 (personal contribution) |
| £16.47 | 204.858 (personal contribution) |
| £16.47 | 223.045 (personal contribution) |
| £16.47 | 82.730 (matching shares) |
| £16.47 | 204.873 (matching shares) |
| £16.47 | 223.059 (matching shares) |
| £16.47 | 82.730 (matching shares) |
| £16.47 | 204.858 (matching shares) |
| £16.47 | 223.045 (matching shares) |
d)
Aggregated information
Aggregated volume Price
2,042.590
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 60.585 (personal contribution) |
| £16.47 | 139.194 (personal contribution) |
| £16.47 | 116.145 (personal contribution) |
| £16.47 | 60.585 (personal contribution) |
| £16.47 | 116.131 (personal contribution) |
| £16.47 | 60.585 (matching shares) |
| £16.47 | 139.194 (matching shares) |
| £16.47 | 116.145 (matching shares) |
| £16.47 | 60.585 (matching shares) |
| £16.47 | 116.131 (personal contribution) |
d)
Aggregated information
Aggregated volume Price
985.280
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 195.213 (personal contribution) |
| £16.47 | 195.199 (personal contribution) |
| £16.47 | 195.213 (matching shares) |
| £16.47 | 195.199 (matching shares) |
d)
Aggregated information
Aggregated volume Price
780.824
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 115.556 (personal contribution) |
| £16.47 | 270.551 (personal contribution) |
| £16.47 | 202.642 personal contribution) |
| £16.47 | 115.540 (personal contribution) |
| £16.47 | 270.537 (personal contribution) |
| £16.47 | 202.642 (personal contribution) |
| £16.47 | 115.556 (matching shares) |
| £16.47 | 270.551 (matching shares) |
| £16.47 | 202.642 (matching shares) |
| £16.47 | 115.540 (matching shares) |
| £16.47 | 270.537 (matching shares) |
| £16.47 | 202.642 (matching shares) |
d)
Aggregated information
Aggregated volume Price
2,354.936
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 42.420 (personal contribution) |
| £16.47 | 100.034 (personal contribution) |
| £16.47 | 73.412 (personal contribution) |
| £16.47 | 42.420 (personal contribution) |
| £16.47 | 100.034 (personal contribution) |
| £16.47 | 73.398 (personal contribution) |
| £16.47 | 42.420 (matching shares) |
| £16.47 | 100.034 (matching shares) |
| £16.47 | 73.412 (matching shares) |
| £16.47 | 42.420 (matching shares) |
| £16.47 | 100.034 (matching shares) |
| £16.47 | 73.398 (matching shares) |
d)
Aggregated information
Aggregated volume Price
863.436
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S A Hussain
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 199.970 (personal contribution) |
| £16.47 | 236.389 (personal contribution) |
| £16.47 | 202.908 personal contribution) |
| £16.47 | 236.389 (personal contribution) |
| £16.47 | 202.894 (personal contribution) |
| £16.47 | 199.970 (matching shares) |
| £16.47 | 236.389 (matching shares) |
| £16.47 | 202.908 (matching shares) |
| £16.47 | 236.389 (matching shares) |
| £16.47 | 202.894 (matching shares) |
d)
Aggregated information
Aggregated volume Price
2,157.100
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $41.81 | 82.979 (personal contribution) |
| $41.81 | 82.979 (matching shares) |
d)
Aggregated information
Aggregated volume Price
165.958
$41.81
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 67.977 (personal contribution) |
| £16.47 | 127.311 (personal contribution) |
| £16.47 | 92.391 (personal contribution) |
| £16.47 | 67.977 (personal contribution) |
| £16.47 | 127.311 (personal contribution) |
| £16.47 | 92.377 (personal contribution) |
| £16.47 | 67.977 (matching shares) |
| £16.47 | 127.311 (matching shares) |
| £16.47 | 92.391 (matching shares) |
| £16.47 | 67.977 (matching shares) |
| £16.47 | 127.311 (matching shares) |
| £16.47 | 92.377 (matching shares) |
d)
Aggregated information
Aggregated volume Price
1,150.688
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 91.499 (personal contribution) |
| £16.47 | 186.252 (personal contribution) |
| £16.47 | 139.061(personal contribution) |
| £16.47 | 91.483 (personal contribution) |
| £16.47 | 186.252 (personal contribution) |
| £16.47 | 139.061 (personal contribution) |
| £16.47 | 91.499 (matching shares) |
| £16.47 | 186.252 (matching shares) |
| £16.47 | 139.061 (matching shares) |
| £16.47 | 91.483 (matching shares) |
| £16.47 | 186.252 (matching shares) |
| £16.47 | 139.061 (matching shares) |
d)
Aggregated information
Aggregated volume Price
1,667.216
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 62.146 (personal contribution) |
| £16.47 | 113.955 (personal contribution) |
| £16.47 | 87.545 (personal contribution) |
| £16.47 | 62.146 (matching shares) |
| £16.47 | 113.955 (matching shares) |
| £16.47 | 87.545 matching shares) |
d)
Aggregated information
Aggregated volume Price
527.292
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $41.81 | 47.220 (personal contribution) |
| $41.81 | 106.319 (personal contribution) |
| $41.81 | 88.057 (personal contribution) |
| $41.81 | 47.220 (personal contribution) |
| $41.81 | 106.319 (personal contribution) |
| $41.81 | 88.044 (personal contribution) |
| $41.81 | 47.220 (matching shares) |
| $41.81 | 106.319 (matching shares) |
| $41.81 | 88.057 (matching shares) |
| $41.81 | 47.220 (matching shares) |
| $41.81 | 106.319 (matching shares) |
| $41.81 | 88.044 (matching shares) |
d)
Aggregated information
Aggregated volume Price
966.358
$41.81
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.47 | 134.685 (personal contribution) |
| £16.47 | 219.092 (personal contribution) |
| £16.47 | 151.043 (personal contribution) |
| £16.47 | 134.685 (personal contribution) |
| £16.47 | 219.092 (personal contribution) |
| £16.47 | 151.043 (personal contribution) |
| £16.47 | 134.685 (matching shares) |
| £16.47 | 219.092 (matching shares) |
| £16.47 | 151.043 (matching shares) |
| £16.47 | 134.685 (matching shares) |
| £16.47 | 219.092 (matching shares) |
| £16.47 | 151.043 (matching shares) |
d)
Aggregated information
Aggregated volume Price
2,019.280
£16.47
e)
Date of the transaction
2017-04-18
f)
Place of the transaction
n/a
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEKLFFDZFBBBF